Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.68) by 23.53 percent. This is a 79.28 percent increase over losses of $(2.51) per share from the same period last year. The company reported quarterly sales of $2.93 million which beat the analyst consensus estimate of $285.71 thousand by 924.10 percent. This is a 184.35 percent increase over sales of $1.03 million the same period last year.